You are here

  • Home
  • Archive
  • Volume 31, Issue 2
  • Determination of plasma uracil as a screening for dihydropyrimidine dehydrogenase deficiency: clinical application in oncological treatments

Article info

Article menu
Download PDFPDF
Original research
Determination of plasma uracil as a screening for dihydropyrimidine dehydrogenase deficiency: clinical application in oncological treatments

Authors

  1. Correspondence to Dr Eduardo Tejedor-Tejada, Pharmacy, Hospital Universitario Torrecardenas, Almería, Spain; edutejedor91{at}gmail.com
View Full Text

Citation

Tejedor-Tejada E, Rubio Calvo D, García Andreo A
Determination of plasma uracil as a screening for dihydropyrimidine dehydrogenase deficiency: clinical application in oncological treatments
European Journal of Hospital Pharmacy 2024;31:124-126.

Publication history

  • Received December 27, 2021
  • Accepted May 24, 2022
  • First published June 21, 2022.
Online issue publication 
February 22, 2024

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ.